Under construction – not a live service
Sign in
Taking people in ChinaPhase 1/2

Testing ZG006 in People With Advanced Small Cell Lung Cancer

Tests ZG006 for safety and dose in adults with advanced small cell lung cancer.

Plain-language title generated from the registry record
Registry title: Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer

Key facts

Where
Shanghai, ChinaSee the site
Phase
Phase 1/2

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 75 with advanced small cell lung cancer or, in the first part, neuroendocrine carcinoma, who can be tested with the study drug ZG006.

Age
18 to 75 years
Sex
All sexes
Disease stage
Advanced small cell lung cancer (SCLC) or neuroendocrine carcinoma, confirmed by tissue or cell tests. The second part is only for advanced SCLC: de-novo SCLC, transformed SCLC, or large-cell neuroendocrine carcinoma of the lung and composite SCLC. The de-novo cohort in its later stage is limited to third-line or later treatment.
Earlier treatment
For one cohort in the second part, people must have had third-line or later treatment. Nothing else is stated.

Main reasons for not taking part

  • People the investigator judges unsuitable for the study for any reason
  • People who cannot sign the informed consent form
  • People with an ECOG Performance Status above 1
  • People with a life expectancy under 3 months

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Source: NCT06283719, who can take part

Where in China

  • Shanghai Chest HospitalShanghai, ChinaContact: Shun LuTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Trial code
NCT06283719
Record updated
19 October 2026
Original description
This is a multicenter, open-label Phase I/II study consisting of two parts:Read full original descriptionShow less

A Phase I Dose Escalation Study of Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by a Phase II Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer

This is a multicenter, open-label Phase I/II study consisting of two parts:

Part 1 is a Phase I dose-escalation study of ZG006, aimed at evaluating the safety and tolerability of ZG006 in Participants with advanced small-cell lung cancer or neuroendocrine carcinoma. Upon completion of Part 1, the investigators and sponsor will jointly determine two preliminary recommended Phase II doses for Part 2, based on the available safety, preliminary efficacy, and pharmacokinetic data.

Part 2 is a Phase II dose-expansion study of ZG006, designed to explore and confirm the efficacy and safety of ZG006 monotherapy in advanced small-cell lung cancer.

Inclusion: Fully understand the study and voluntarily sign the informed consent form; Male or female 18~75 years of age; Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1; Life expectancy ≥ 3 months; Participants with histologically or cytologically confirmed advanced solid tumors who also fulfill the following: Part 1: advanced small-cell lung cancer (SCLC) or neuroendocrine carcinoma.Part 2: advanced SCLC.Specifically for Part 2 Cohort 1: de-novo SCLC (composite SCLC excluded).Stage 2 restricted to third-line or later.Cohort 2: transformed SCLC.Cohort 3: large-cell neuroendocrine carcinoma of the lung and composite SCLC.

Exclusion: Participants were deemed unsuitable for participating in the study by the investigator for any reason.

ClinicalTrials.gov NCT06283719